

【書 籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
岡田賢司	百日咳	藤実正太	小児科診療	株式会社診断と治療社	東京	2023	165-6
岡田賢司	百日咳	加藤元博・高橋尚人	小児臨床検査ガイド	文光堂	東京	2023	354-7
中野貴司	COVID-19 ワクチン接種後の死亡者は多発しているのか？	菅谷憲夫	インフルエンザ診療ガイド 2023-24	日本医事新報社	東京	2023	158-60
間辺利江	COVID-19 の発生と世界的流行の拡散	山田 満 堀江正伸	新しい国際協力論 第3版	明石書店	東京	2023	
中野貴司	インフルエンザワクチンとCOVID-19 ワクチンの同時接種について	菅谷憲夫	インフルエンザ / 新型コロナウイルス感染症 診療ガイド 2022-23	日本医事新報社	東京	2022	274-6
入江 伸、伊藤一弥、福島若葉、大藤さところ、他	インフルエンザの予防と対策	廣田良夫	2021 年版 米国予防接種諮問委員会 (ACIP) 勧告、インフルエンザの予防と対策	(財)日本公衆衛生協会	東京	2022	
岡田賢司	百日咳	水口雅、山形崇倫	臨床ガイド小児科 専門医の診断・治療	南山堂	東京	2021	586-90
岡田賢司	百日咳菌	岡田浩一、黒川峰夫	臨床検査を使いこなす	南山堂	東京	2021	262-3
入江 伸、伊藤一弥、福島若葉、大藤さところ、他	インフルエンザの予防と対策	廣田良夫	2020 年版 米国予防接種諮問委員会 (ACIP) 勧告、インフルエンザの予防と対策	(財)日本公衆衛生協会	東京	2021	
岡田賢司	DPT-IPV(百日咳,ジフテリア,破傷風,ポリオ)	岡部信彦	予防接種の手びき 2020-2021	近代出版	東京	2020	158-78
岡田賢司	小児の百日咳	福井次矢	今日の診断指針 第8版	医学書院	東京	2020	1855-7
岡田賢司	医療関係者のためのワクチンガイドライン 第3版	三嶋廣繁	一般社団法人日本環境感染症学会	協和企画	東京	2020	
岡田賢司	予防接種ガイドライン 2020 年度版	岡部信彦	予防接種ガイドライン 2020 年度版	公益財団法人予防接種リサーチセンター	東京	2020	

【雑 誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ito W, Fukumori T, Asaoka N, Imakita N, Nishimura T, Furukawa R, Nishihara Y, Fujikura H, Sekine T, Yamaguchi N, Hirata Y, Miyamoto S, Kanno T, Katano H, Suzuki T, Kasahara K.	Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.	J Infect Chemother.	S1341-321X (24)	00001-1	2024
Tanaka M, Okubo R, Hoshi SL, Kondo M.	Cost-effectiveness analysis of pertussis booster vaccination for adolescents	Vaccine			2024 in press
Arashiro T, Arima Y, Kuramochi J, Muraoka H, Sato A, Chubachi K, Oba K, Yanai A, Arioka H, Uehara Y, Ihara G, Kato Y, Yanagisawa N, Nagura Y, Yanai H, Ueda A, Numata A, Kato H, Oka H, Nishida Y, Ooki T, Nidaira Y, Stucky A, Suzuki T, Smith C, Hibberd M, Ariyoshi K, Suzuki M.	Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies.	Euro Surveill.	28(4)	2300034	2023
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y	Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination.	Hum Vaccin Immunother.	19(2)	2226575	2023
Arashiro T, Arai S, Kinoshita R, Otani K, Miyamoto S, Yoneoka D, Kamigaki T, Takahashi H, Hibino H, Okuyama M, Hayashi A, Kikuchi F, Morino S, Takanashi S, Wakita T, Tanaka-Taya K, Suzuki T, Suzuki M	National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.	Influenza Other Respi Viruses.	17(2)	e13094.	2023
Mukai E, Fukushima W, Morikawa S, Nakata K, Hiroi S, Fujioka M, Matsushita T, Kubota M, Yagi Y, Takechi T, Takasaki Y, Shindo S, Yamashita Y, Yokoyama T, Kiyomatsu Y, Matsumoto K, Maeda A, Kondo K, Ito K, Kase T, Ohfuji S, Hirota Y.	No association between inactivated influenza vaccination and influenza viral load at diagnosis among young Japanese children: An observational study of the 2013/2014 through 2017/2018 influenza seasons.	Influenza Other Respi Viruses.	17(10)	e13213.	2023

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T.	Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.	iScience.	26(2)	105969	2023
Miyamoto S, Kuroda Y, Kanno T, Ueno A, Shiwa-Sudo N, Iwata-Yoshikawa N, Sakai Y, Nagata N, Arashiro T, Ainai A, Morikawa S, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Fukushi S, Takahashi Y, Maeda K, Suzuki T	Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: implications for vaccine dose interval.	iScience.	26(5)	106694	2023
Hara M, Ohta Y, Fusazaki N, Hirota Y.	Effectiveness of BNT162b2 vaccine against symptomatic SARS-CoV-2 infection in children aged 5 – 11 years in Japan during Omicron variant predominate periods.	J Epidemiol.			2023 in press
Watanabe K, Nojima M, Nakase H, Sato T, Matsuura M, Aoyama N, Kobayashi T, Sakuraba H, Nishishita M, Yokoyama K, Esaki M, Hirai F, Nagahori M, Nanjo S, Omori T, Tanida S, Yokoyama Y, Moriya K, Maemoto A, Handa O, Ohmiya N, Tsuchiya K, Shinzaki S, Kato S, Uraoka T, Tanaka H, Takatsu N, Nishida A, Umeno J, Nakamura M, Mishima Y, Fujiya M, Tsuchida K, Hiraoka S, Okabe M, Toyonaga T, Matsuoka K, Andoh A, Hirota Y#, Hisamatsu T#; J-COMBAT study group. #Contributed equally	Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.	J Gastroenterol.	58	1015-29	2023
Nakashima K, Homma Y, Taniguchi J, Kubota N, Otsuki A, Ito H, Otsuka Y, Kondo K, Ohfuji S, Fukushima W, Hirota Y	Immunogenicity and safety of influenza vaccine in patients with lung cancer receiving immune checkpoint inhibitors: A single-center prospective cohort study	J Infect Chemother.	29(11)	1038-45	2023

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shiwa-Sudo N, Sakai Y, Iwata-Yoshikawa N, Watanabe S, Yamada S, Kuroda Y, Yamamoto T, Shirakura M, Fujisaki S, Miyazaki K, Miura H, Nagata S, Fukushi S, Maeda K, Hasegawa H, Suzuki T, Nagata N.	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.	J Virol.	97(1)	e0136622.	2023
Kamegai K, Iwamoto N, Itoh N, Ishikane M, Asai Y, Akazawa N, Fuwa N, Takasaki J, Hojo M, Hangaishi A, Togano T, Teruya K, Kanno T, Takahashi K, Miyamoto S, Hirata Y, Saito T, Katano H, Suzuki T, Ohmagari N,	Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant among Immunocompromised Patients.	Open Forum Infect Dis.	10 (Suppl 2)	S293-4	2023
Do TV, Manabe T, Vu GV, Nong VM, Fujikura Y, Phan D, Pham TT, Do CD, Doan TT, Nguyen NT, Nguyen TQ, Dong TV, Luong CQ, Manabe H, Kambayashi D, Hoang AV, Vu NV, Trinh GK, Do SN, Kamiya T, Ohara H, Nguyen CV, Dang TQ, Kudo K, Dao CX.	Clinical characteristics and mortality risk among critically ill patients with COVID-19 owing to the B.1.617.2 (Delta) variant in Vietnam: A retrospective observational study.	PLoS One.	18(1)	e0279713.	2023
Hosoya T, Oba S, Komiya Y, Kawata D, Kamiya M, Iwai H., Miyamoto S, Kataoka M, Tobiume M, Kanno T, Ainai A, Sato H, Hirakawa A, Mitsui Y, Satoh T, Wakabayashi K., Yamada T, Otomo Y, Miyazaki Y., Hasegawa H, Suzuki T, Yasuda S.	Apple-shaped obesity: A risky soil for cytokine-accelerated severity in COVID-19.	Proc Natl Acad Sci U S A.	120(22)	e2300155120	2023

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miyamoto S, Nishiyama T, Ueno A, Park H, Kanno T, Nakamura N, Ozono S, Aihara K, Takahashi K, Tsuchihashi Y, Ishikane M, Arashiro T, Saito S, Ainai A, Hirata Y, Iida S, Katano H, Tobiume M, Tokunaga K, Fujimoto T, Suzuki M, Nagashima M, Nakagawa H, Narita M, Kato Y, Igari H, Fujita K, Kato T, Hiyama K, Shindou K, Adachi T, Fukushima K, Nakamura-Uchiyama F, Hase R, Yoshimura Y, Yamato M, Nozaki Y, Ohmagari N, Suzuki M, Saito T, Iwami S, Suzuki T.	Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.	Proc Natl Acad Sci U S A.	120(52)	e2314808120	2023
Suzuki T, Morioka S, Yamamoto K, Saito S, Iida S, Teruya K, Takasaki J, Hojo M, Hayakawa K, Kutsuna S, Miyamoto S, Ozono S, Suzuki T, Kodama E. N, Ohmagari N	Nasopharyngeal SARS-CoV-2 may not be dispersed by a high-flow nasal cannula.	Sci Rep.	13(1)	2669	2023
Sasaki M, Tabata K, Kishimoto M, Itakura Y, Kobayashi H, Ariizumi T, Uemura K, Toba S, Kusakabe S, Maruyama Y, Iida S, Nakajima N, Suzuki T, Yoshida S, Nobori H, Sanaki T, Kato T, Shishido T, Hall WW, Orba Y, Sato A, Sawa H.	S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.	Sci Transl Med.	15(679)	eabq4064.	2023
Suita A, Ohfuji S, Kasamatsu A, Kondo K, Nakata H, Kita T, Deguchi A, Fujimoto M, Iba K, Sakamoto H, Iwasaka K, Sakamoto N, Sakamoto H, Yodoi Y, Kido Y, Nakagama Y, Konishi A, Mukai E, Matsumoto K, Matsuura T, Kase T, Takeya H, Fukushima W, Hirota Y.	Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities.	Vaccine X.	15	100412	2023
Kato H, Hozawa T, Fukushima W, Nobusawa E, Hirota Y	Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective	Vaccine.	41(31)	4625-31	2023
Fukushima S, Kiyohara T, Nakano T, Tada Y, Hamada A	Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults.	Vaccine.	41(32)	4726-30	2023

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ueno M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, Saito S, Ashida S, Yoshida I, Nagashima M, Asakura H, Yaoita Y, Suzuki J, Sadamasu K, Yoshimura K, Kutsuna S, Shiwa-Sudo N, Nagata N, Suzuki T, Suzuki A, Okamoto M, Kimura M, Ohmagari N, Miura R, Ishizaka Y.	Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.	Antiviral Res.	201	105297	2022
Maruki T, Iwamoto N, Kanda K, Okumura N, Yamada G, Ishikane M, Ujiie M, Saito M, Fujimoto T, Kageyama T, Saito T, Saito S, Suzuki T, Ohmagari N.	Two cases of breakthrough SARS-CoV-2 infections caused by the Omicron variant (B.1.1.529 lineage) in international travelers to Japan.	Clin Infect Dis.	75(1)	e354-6.	2022
Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, Nagashima M, Moriya A, Suzuki M, Hojo M, Kanno T, Saito S, Miyamoto S, Ainai A, Tobiume M, Arashiro T, Fujimoto T, Saito T, Yamato M, Suzuki T, Ohmagari N.	Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees.	Emerg Infect Dis.	28(5)	998-1001	2022
Nakashima K, Ishida M, Matsui H, Yoshida C, Nagai T, Shiraga M, Nakaoka H, Otsuka Y, Nakagama Y, Kaku N, Nitahara Y, Kido Y, Hirota Y	Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.	Hum Vaccin Immunother.	18(6)	2140549	2022
Aoshima M, Ohfuji S.	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic.	Hum Vaccin Immunother.	18(7)	2147353	2022
Takagi A, Ohfuji S, Nakano T, Kumihashi H, Kano M, Tanaka T.	Incidence of mumps deafness in Japan, 2005-2017: analysis of Japanese insurance claims database.	J Epidemiol.	32(1)	21-6	2022
Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Abukawa D, Hisamatsu T, J-COSMOS group (J-COSMOS 研究グループメンバーリストの57 番目)	Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)	J Gastroenterol.	57(3)	174-84	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Halfmann PJ, Nakajima N, Sato Y, Takahashi K, Accola M, Chiba S, Fan S, Neumann G, Rehrauer W, Suzuki T, Kawaoka Y.	SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters.	J Infect Dis.	225(2)	282-6.	2022
Ohira S, Nakano T, et al.	Changes in serum antibody titers after vaccination for COVID-19 and evaluation of post-vaccination health conditions	Kawasaki Medical Journal	48	73-85	2022
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Aina A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T.	Vaccination-infection interval determines cross-neutralization potency to SARS- CoV-2 Omicron after breakthrough infection by other variants.	Med (N Y).	3(4)	249-61	2022
Seki Y, Yoshihara Y, Nojima K, Momose H, Fukushi S, Moriyama S, Wagatsuma A, Numata N, Sasaki K, Kuzuoka T, Yato Y, Takahashi Y, Maeda K, Suzuki T, Mizukami T, Hamaguchi I.	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.	Med (N Y).	3(6)	406-21	2022
Iwata-Yoshikawa N, Kakizaki M, Shiwa-Sudo N, Okura T, Tahara M, Fukushi S, Maeda K, Kawase M, Asanuma H, Tomita Y, Takayama I, Matsuyama S, Shirato K, Suzuki T, Nagata N, Takeda M.	Essential role of TMPRSS2 in SARS-CoV-2 infection in murine airways.	Nat Commun.	13(1)	6100	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, Darling TL, Joshi A, Loeber S, Singh G, Foster SL, Ying B, Case JB, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio JE, Hernandez-Ortiz JP, Henry AR, Ciouderis K, Florek KR, Patel M, Odle A, Wong LR, Bateman AC, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche AS, Sordillo EM, Chang LA, van Bakel H, Simon V; Consortium Mount Sinai Pathogen Surveillance (PSP) study group, Douek DC, Sullivan NJ, Thackray LB, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby RJ, Seder RA, Suthar MS, García-Sastre A, Schotsaert M, Suzuki T, Boon ACM, Diamond MS, Kawaoka Y.	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.	Nature.	603 (7902)	687-92	2022
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y.	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.	Nature.	607 (7917)	119-27	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y.	Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents.	Nature.	612 (7940)	540-5	2022
Takei S, Ai T, Yamamoto T, Igawa G, Kanno T, Tobiume M, Hiki M, Saito K, Khasawneh A, Wakita M, Misawa S, Miida T, Okuzawa A, Suzuki T, Takahashi K, Naito T, Tabe Y.	Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment.	PLoS One.	17(9)	e0274181	2022
Takei S, Ai T, Yamamoto T, Igawa G, Kanno T, Tobiume M, Hiki M, Saito K, Khasawneh A, Wakita M, Misawa S, Miida T, Okuzawa A, Suzuki T, Takahashi K, Naito T, Tabe Y.	Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-3 immunoassays by comparison with neutralizing antibodies and clinical assessment.	PLoS One.	17(10)	e0274182	2023
Iwata-Yoshikawa N, Shiwa N, Sekizuka T, Sano K, Ainai A, Hemmi T, Kataoka M, Kuroda M, Hasegawa H, Suzuki T, Nagata N.	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.	Sci Adv.	8(1)	eabh3827.	2022
Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, Tonouchi K, Terahara K, Sun L, Takano T, Nishiyama A, Shinkai M, Oba K, Nakamura-Uchiyama F, Shimizu H, Suzuki T, Matsumura T, Isogawa M, Takahashi Y.	SARS-CoV-2 Omicron- neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine.	Sci Immunol.	7(70)	eabn8590	2022
Okada K, Horikoshi Y, Nishimura N, Ishii S, Nogami H, Motomura C, Miyairi I, Tsumura N, Mori T, Ito K, Honma S, Nagai K, Tanaka H, Hayakawa T, Abe C, Ouchi K	Clinical evaluation of a new rapid immunochromatographic test for detection of Bordetella pertussis antigen	Sci Rep.	12(1)	8069	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takahashi M, Ai T, Sinozuka K, Baba Y, Igawa G, Nojiri S, Yamamoto T, Yuri M, Takei S, Saito K, Horiuchi Y, Kanno T, Tobiume M, Khasawneh A, Paran FJ, Hiki M, Wakita M, Miida T, Suzuki T, Okuzawa A, Takahashi K, Naito T, Tabe Y.	Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies.	Sci Rep.	12(1)	14909	2022
Tokiya M, Hara M, Matsumoto A, Ashenagar MS, Nakano T, Hirota Y	Association of Vaccine Confidence and Hesitancy in Three Phases of COVID-19 Vaccine Approval and Introduction in Japan	Vaccines (Basel).	10(3)	423	2022
Ashenagar MS, Matsumoto A, Sakai H, Tokiya M, Hara M, Hirota Y	Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine	Vaccines (Basel).	10(4)	487	2022
Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, Sonoda N, Tanaka M, Arase Y, Tanaka Y, Nakashima H, Irie S, Hirota Y	Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case-Control Study	Vaccines (Basel).	10(5)	779	2022
Matsumoto A, Hara M, Ashenagar MS, Tokiya M, Sawada T, Iwasaka C, Furukawa T, Kitagawa K, Miyake Y, Hirota Y	Variant Allele of ALDH2, rs671, Associates with Attenuated Post-Vaccination Response in Anti-SARS-CoV-2 Spike Protein IgG: A Prospective Study in the Japanese General Population	Vaccines (Basel).	10(7)	1035	2022
Tokiya M, Hara M, Matsumoto A, Ashenagar MS, Nakano T, Hirota Y	Acceptance of Booster COVID-19 Vaccine and Its Association with Components of Vaccination Readiness in the General Population: A Cross-Sectional Survey for Starting Booster Dose in Japan	Vaccines (Basel).	10(7)	1102	2022
Ohfuji S, Tanaka T, Nakano T, Kase T, Kondo K, Fukushima W, Hirota Y.	Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.	Vaccine.	40(7)	988-93	2022
Tanaka M, Okubo R, Hoshi SL, Ishikawa N, Kondo M	Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.	Vaccine.	40(7)	1010-8	2022
Hoshi SL, Okubo R, Tabuchi K, Seposo X, Shono A, Kondo M.	Cost-effectiveness analyses of monovalent mumps vaccination programs for Japanese children	Vaccine.	40(37)	5513-22	2022
Matsuura T, Fukushima W, Nakagama Y, Kido Y, Kase T, Kondo K, Kaku N, Matsumoto K, Suita A, Komiya E, Mukai E, Nitahara Y, Konishi A, Kasamatsu A, Nakagami-Yamaguchi E, Ohfuji S, Kaneko Y, Kaneko A, Kakeya H, Hirota Y.	Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan.	Vaccine.	40(38)	5631-40	2022

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nakashima K, Suzuki K, Aoshima M, Murabata M, Kondo K, Ohfuji S, Fukushima W, Maeda A, Hirota Y; Pneumonia in Elderly People Study Group.	Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.	Vaccine.	40(46)	6589-98	2022
Hoshi SL, Shono A, Seposo X, Okubo R, Kondo M.	Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly	Vaccine.	40(49)	7057-64	2022
Tsurane K, Umehara N, Nakayama T, Okada K, Inoue M, Ogawa K, Sago H, Miyasaka N, Yamaguchi K	Pertussis, diphtheria, and tetanus antibodies seroprevalence in pregnant women and neonates, as a preliminary data for introduction of preconception or prenatal DTaP vaccination among Japanese society	Vaccine.	40(49)	7122-9	2022
Ogawa T, Uemura T, Matsuda W, Sato M, Ishizuka K, Fukaya T, Kinoshita N, Nakamoto T, Ohmagari N, Katano H, Suzuki T, Hosaka S.	SARS-CoV-2 Leakage From the Gas Outlet Port During Extracorporeal Membrane Oxygenation for COVID-19.	ASAIO J.	67(5)	511-6	2021
Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.	Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.	BMC Infect Dis.	21(1)	489	2021
Manabe T, Phan D, Nohara Y, Kambayashi D, Nguyen TH, Van Do T, Kudo K. Spatiotemporal distribution of COVID-19 during the first 7 months of the epidemic in Vietnam.	Spatiotemporal distribution of COVID-19 during the first 7 months of the epidemic in Vietnam.	BMC Infect Dis.	21(1)	1124	2021
Yamaoka Y, Miyakawa K, Jeremiah SS, Funabashi R, Okudela K, Kikuchi S, Katada J, Wada A, Takei T, Nishi M, Shimizu K, Ozawa H, Usuku S, Kawakami C, Tanaka N, Morita T, Hayashi H, Mitsui H, Suzuki K, Aizawa D, Yoshimura Y, Miyazaki T, Yamazaki E, Suzuki T, Kimura H, Shimizu H, Okabe N, Hasegawa H, Ryo A.	Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.	Cell Rep Med.	2(6)	100311	2021

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shionoya K, Yamasaki M, Iwanami S, Ito Y, Fukushi S, Ohashi H, Saso W, Tanaka T, Aoki S, Kuramochi K, Iwami S, Takahashi Y, Suzuki T, Muramatsu M, Takeda M, Wakita T, Watashi K.	Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.	Front Microbiol.	12	651403	2021
Serre-Yu Wong, R. Dixon, V. Martinez Pazos, S. Gnjatc, J. Colombel, K. Cadwell, for the ICARUS-IBD Working Group (ICARUS-IBD Working Group メンバーリストの24番目)	Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies	Gastroenterology	161(2)	715-8	2021
Morikawa S, Otsuka M, Yumisashi T, Motomura K	A longitudinal study on respiratory viral infection for healthy volunteers	Health Sci Rep	4(4)	e413	2021
Anzures A, Naka I, Miki S, Nakayama-Hosoya K, Isshiki M, Watanabe Y, Nakamura-Hoshi M, Seki S, Matsumura T, Takano T, Onodera T, Adachi Y, Moriyama S, Terahara K, Tachikawa N, Yoshimura Y, Sasaki H, Horiuchi H, Miyata N, Miyazaki K, Koga M, Ikeuchi K, Nagai H, Saito M, Adachi E, Yotsuyanagi H, Kutsuna S, Kawashima A, Miyazato Y, Kinoshita N, Kouno C, Tanaka K, Takahashi Y, Suzuki T, Matano T, Ohashi J, Kawana-Tachikawa A.	Association of HLA-DRB1*09:01 with severe COVID-19.	HLA.	98(1)	37-42	2021
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y.	Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.	Immunity.	54(8)	1841-52	2021

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Onodera T, Kita S, Adachi Y, Moriyama S, Sato A, Nomura T, Sakakibara S, Inoue T, Tadokoro T, Anraku Y, Yumoto K, Tian C, Fukuhara H, Sasaki M, Orba Y, Shiwa N, Iwata N, Nagata N, Suzuki T, Sasaki J, Sekizuka T, Tonouchi K, Sun L, Fukushi S, Satofuka H, Kazuki Y, Oshimura M, Kurosaki T, Kuroda M, Matsuura Y, Suzuki T, Sawa H, Hashiguchi T, Maenaka K, Takahashi Y.	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site.	Immunity.	54(10)	2385-98	2021
Nakamura Y, Katano H, Nakajima N, Sato Y, Suzuki T, Sekizuka T, Kuroda M, Izutani Y, Morimoto S, Maruyama J, Koie M, Kitamura T, Ishikura H.	SARS-CoV-2 is localized in cardiomyocytes: a postmortem biopsy case.	Int J Infect Dis.	111	43-6.	2021
Tsukada A, Suzuki M, Kishino Y, Misumi K, Igari T, Nakajima N, Sato Y, Suzuki T, Katsuno T, Kusaba Y, Tsujimoto Y, Sakamoto K, Hashimoto M, Terada J, Takasaki J, Izumi S, Hojo M, Sugiyama H.	A Kidney Transplant Patient Who Died of COVID-19-associated Severe Acute Respiratory Distress Syndrome.	Intern Med.	60(14)	2297-300.	2021
Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, Nomura T, Suzuki T, Nishioka K, Ando S, Ejima K, Koizumi Y, Tanaka T, Aoki S, Kuramochi K, Suzuki T, Hashiguchi T, Maenaka K, Matano T, Muramatsu M, Saijo M, Aihara K, Iwami S, Takeda M, McKeating JA, Wakita T.	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.	iScience.	24(4)	102367	2021
Ohfuji S, Takagi A, Nakano T, Kumihashi H, Kano M, Tanaka T.	Mumps-related disease burden in Japan: analysis of JMDC health insurance reimbursement data for 2005-2017.	J Epidemiol.	31(8)	464-70	2021
Fujigaki H, Inaba M, Osawa M, Moriyama S, Takahashi Y, Suzuki T, Yamase K, Yoshida Y, Yagura Y, Oyamada T, Takemura M, Doi Y, Saito K.	Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients.	J Immunol.	206(10)	2393-401.	2021

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mihara Y, Yoshino S, Nakatani K, Nishimura T, Kan H, Yamamura Y, Tanaka E, Ishii S, Shimonodan H, Okada K, Nishiguchi T	Bordetella pertussis is a common pathogen in infants hospitalized for acute lower respiratory tract infection during the winter season	J Infect Chemother.	27(3)	497-502	2021
Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H.	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.	J Virol.	96(4)	e0155121	2022
Iida S, Arashiro T, Suzuki T.	Insights into Pathology and Pathogenesis of Coronavirus Disease 2019 from a Histopathological and Immunological Perspective.	JMA J.	4(3)	179-86.	2021
Sakuraba M, Watanabe S, Nishiyama Y, Takahashi K, Nakamichi K, Suzuki M, Nawata T, Komai K, Gono T, Takeno M, Suzuki T, Kimura K, Kuwana M.	Infratentorial onset of progressive multifocal leukoencephalopathy in a patient with systematic lupus erythematosus complicated with lymphoma: a case report.	Mod Rheumatol Case Rep.	5(2)	272-7.	2021
Miki S, Sasaki H, Horiuchi H, Miyata N, Yoshimura Y, Miyazaki K, Matsumura T, Takahashi Y, Suzuki T, Matano T, Kawana-Tachikawa A, Tachikawa N.	On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19.	PLoS One.	16(7)	e0254640.	2021
Nomura T, Yamamoto H, Nishizawa M, Hau TTT, Harada S, Ishii H, Seki S, Nakamura-Hoshi M, Okazaki M, Daigen S, Kawana-Tachikawa A, Nagata N, Iwata-Yoshikawa N, Shiwa N, Iida S, Katano H, Suzuki T, Park ES, Maeda K, Suzuki Y, Ami Y, Matano T.	Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.	PLoS Pathog.	17(7)	e1009668.	2021

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Einfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y.	Characterization of a new SARS-CoV-2 variant that emerged in Brazil.	Proc Natl Acad Sci U S A.	118(27)	e2106535118.	2021
Ohfuji S, Okada K, Mouri Y, Mihara Y, Ishii S, Miyata A, Fujino M, Motomura C, Ito H, Ohta M, Kasahara Y, Nakamura H, Hasui M, Yoshikawa T, Tanaka T, Nakano T, Koshida R, Araki K, Hara M, Hirota Y.	Effectiveness of four doses of pertussis vaccine during infancy diminished in elementary school age: A test-negative case-control study in Japan.	Vaccine.	39(1)	11-7	2021
Hara M, Koshida R, Nakano T.	Parents' views on mumps, mumps vaccine, and the factors associated with vaccination in Japan	Vaccine.	39(52)	7677-83	2021
Hara M, Ishibashi M, Nakane A, Nakano T, Hirota Y.	Differences in COVID-19 vaccine acceptance, hesitancy, and confidence between healthcare workers and the general population in Japan	Vaccines (Basel).	9(12)	1389	2021
Matsumoto K, Fukushima W, Morikawa S, Fujioka M, Matsushita T, Kubota M, Yagi Y, Takasaki Y, Shindo S, Yamashita Y, Yokoyama T, Kiyomatsu Y, Hiroi S, Nakata K, Maeda A, Kondo K, Ito K, Kase T, Ohfuji S, Hirota Y.	Influence of prior influenza vaccination on current influenza vaccine effectiveness in children aged 1 to 5 years.	Vaccines (Basel).	9(12)	1447	2021

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kimura M, Egawa K, Ozawa T, Kishi H, Shimojima M, Taniguchi S, Fukushi S, Fujii H, Yamada H, Tan L, Sano K, Katano H, Suzuki T, Morikawa S, Saijo M, Tani H.	Characterization of pseudotyped vesicular stomatitis virus bearing the heartland virus envelope glycoprotein.	Virology.	556	124-32.	2021
Hara M, Koshida R, Araki K, Kondo M, Hirota Y.	Determinants of self-paid rotavirus vaccination status in Kanazawa, Japan, including socioeconomic factors, parents' perception, and children's characteristic	BMC Infect Dis.	20(1)	712	2020
Shono A, Hoshi SL, Kondo M.	Maternal influenza vaccination relates to receiving relevant information among pregnant women in Japan	Hum Vaccin Immunother.	16(6)	1364-70	2020
Ohfuji S, Deguchi M, Tachibana D, Koyama M, Takagi T, Yoshioka T, Urae A, Ito K, Kase T, Maeda A, Kondo K, Fukushima W, Hirota Y; Osaka Pregnant Women Influenza Study Group.	Safety of influenza vaccination on adverse birth outcomes among pregnant women: A prospective cohort study in Japan.	Int J Infect Dis.	93	68-76	2020
Washio M, Kondo K, Fukushima W, Ohfuji S, Fujisawa N, Matsumoto T, Tashiro H, Nogami H, Iwanaga T, Nakanishi Y, Kitazono T, Suzuki, Hirota Y.	Hypoalbuminemia, pneumococcal vaccination and the risk of community-acquired pneumonia in the elderly: a case-control study in Southern Japan.	Int Med J	27(1)	24-7	2020
Fukusumi M, Kanagawa Y, Ohfuji S, Miyazaki K, Matsui T, Mizoguchi K, Yuguchi Y, Fukushima W, Oishi K, Hirota Y.	Risk of seasonal influenza by occupation in a railway company in a metropolitan area of Japan during three influenza seasons.	Jpn J Infect Dis.	73(4)	268-71	2020
Manabe T, Akatsu H, Kotani K, Kudo K.	Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020.	Respir Investig.	58(5)	409-18	2020
Nakanishi H, Suzuki M, Maeda H, Nakamura Y, Ikegami Y, Takenaka Y, Mori Y, Hasuo T, Hasegawa C	Differential Diagnosis of COVID-19: Importance of Measuring Blood Lymphocytes, Serum Electrolytes, and Olfactory and Taste Functions	Tohoku J. Exp. Med.	252(2)	109-19	2020
Kase T, Inoue M, Morikawa S, Kumashiro H, Hiroi S, Nakata K, Ito K, Ishibashi M, Tsuru T, Irie S, Maeda A, Ohfuji S, Fukushima W, Hirota Y.	Comparison of immunogenicity between candidate influenza A(H3N2) virus vaccine strains in Japan: A randomized controlled trial using a monovalent vaccine of A/Saitama/103/2014 (CEXP-002) and A/Hong Kong/4801/2014 (X-263).	Vaccine.	38(42)	6524-32	2020
Hoshi SL, Shono A, Seposo X, Okubo I, Kondo M.	Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan.	Vaccine.	38(46)	7363-71	2020

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
岡田賢司	就学前までに受けてほしいワクチン	保育と保健	29(1)	56-8	2023
岡田賢司	百日咳含有ワクチン—成人を中心に—	公衆衛生	87(9)	930-3	2023
中野貴司	インフルエンザと COVID-19 —これまでを振り返り、 今後に備える	小児科	64(11)	1187-95	2023
中野貴司	新型コロナワクチン	臨床と微生物	50(6)	731-7	2023
中野貴司	インフルエンザワクチンの有用性と問題点	臨床と研究	100(12)	1478-82	2023
赤津裕康, 平松克仁, 田中創始, 間辺利江, 荒川和幸, 兼松孝好, 長谷川千尋, 久米充芳, 丸山光生, 中村 敦, 鈴木幹三, 大原弘隆	抗体価測定により新型コロナウイルス感染症が示唆された1例	感染症学雑誌	96(5)	204-9	2022
中野貴司	小児におけるワクチンの効果 (【特集】with コロナの 小児医療の変化)	小児外科	第54巻、 第6号	556-9	2022
中野貴司	新型コロナワクチンの成果と課題	皮膚病診療	第45巻、 第1号	14-9	2023
中野貴司	COVID-19 ワクチンの現状と今後	臨床検査	第66巻、 第8号	932-8	2022
岡田賢司	4種混合ワクチン	臨床と研究	99(4)	423-8	2022
中野貴司	知りたい! 聞きたい! 養護教諭なんでも質問 BOX 「新型コロナウイルスワクチンとは、どういうものですか? そのしくみや効果、副反応などについて教えてください。」	健康教室	72(10)	6-8	2021
中野貴司	新型コロナワクチン Q&A —患者さんにはこう説明する	週刊日本医事新報	5065	18-39	2021
中野貴司	mRNA ワクチン	内科総合誌 Medical Practice	38(7)	1110-2	2021
中野貴司	小児と COVID-19 ワクチン	小児感染免疫	33(3)	199	2021
中村敦	特集 新型コロナウイルス感染症Ⅷ インフルエンザ シーズンにおける新型コロナウイルス感染症診療	名古屋医報	1472	15-7	2021
田中創始	新型コロナウイルス感染症について～ COVID-19 ワ クチンと変異株を中心に～	名古屋医報 8月号	1479	6-8	2021
中村敦	第2章新型コロナウイルス感染症の基礎知識 4. 「COVID-19では静脈血栓症のリスクが増加しますか?」	INFECTION CONTROL 2021年 春増刊 (メディカ 出版, 大阪)	春増刊	35-8	2021
中村敦	第2章新型コロナウイルス感染症の基礎知識 5. 「現在, COVID-19 の治療薬やワクチンにはどのようなものが 検討されているのでしょうか?」	INFECTION CONTROL 2021年 春増刊 (メディカ 出版, 大阪)	春増刊	39-45	2021

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	
福島若葉, 森川佐依子, 松本一寛, 藤岡雅司, 松下享, 久保田恵巳, 八木由奈, 高崎好生, 進藤静生, 清松由美, 廣井聡, 中田恵子, 伊藤一弥, 前田章子, 近藤亨子, 迎恵美子, 加瀬哲男, 大藤さとこ, 廣田良夫.	3歳未満小児におけるインフルエンザワクチンの有効性 :2018/19~2019/20 シーズンのまとめ (厚生労働省研究班報告として)	IASR		42	255-7	2021
長谷川千尋	SARS-CoV-2 の PCR 検査が陰性であったが現病歴と胸部 CT 検査から COVID-19 が疑われ迅速抗体検査で診断に至った 2 例	日本感染症学会雑誌 オンライン感染症トピックス				2020
中村敦	新型コロナウイルス感染症との付き合いかたー「正しく恐れる」ためにー	名古屋市立大学編 名古屋市大ブックス	4		6-17	2020
中村敦	Web 座談会 新型コロナウイルスワクチンの現状と課題	現代医学		68(1)	1-13	2020
中村敦	Web 座談会 新型コロナウイルス感染症 (COVID-19) に対する現状の知見と対応	現代医学		67(2)	1-9	2020
中村敦	特集 新型コロナウイルス感染症II 新型コロナウイルス感染症の第 2 波と対峙するために	名古屋医報		1466	29-31	2020
大藤さとこ	小児感染症 Q&A インフルエンザワクチン接種の効果と有効性について、諸外国のデータとともに教えてください。	Up-to-date 子どもの感染症		8(s1)	24-5	2020
福島若葉, 森川佐依子, 松本一寛, 藤岡雅司, 松下享, 久保田恵巳, 八木由奈, 高崎好生, 進藤静生, 清松由美, 廣井聡, 中田恵子, 伊藤一弥, 近藤亨子, 前田章子, 加瀬哲男, 大藤さとこ, 廣田良夫.	3歳未満小児におけるインフルエンザワクチンの有効性 : 2018/19 シーズン (厚生労働省研究班報告として).	IASR		41	204-5	2020